Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

CML Expert Opinions

Can we safely stop TKI therapies? Experience from the STOP trials

Delphine Rea, Hôpital Saint-Louis, Paris, France

Please wait as the educational presentation will start automatically. You can also click on the slides to jump to certain sections of the presentation. Please share your feedback below, and view the other Virtual Education Program modules.

 

webcast-button
delphine-rea

 

Issues covered

  • Unmet medical needs in currently available CML treatments
  • Treatment options for CML with T315I mutation
  • Treatment options after TKI intolerance
  • Trial results with bosutinib, ponatinib, omacetaxine
  • Results from studies investigating imatinib + interferon

Has this been helpful? Please provide your comments here:

Facteur de variabilité de la réponse au ITK</li>
              <li>Les trois grand mécanismes de résistance</li>
              <li>La réponse au traitement</li>
              <li>Autres inhibiteurs de tyrosine kinase: le Nilotinib et le Dasatinib